Cambrex Capabilities Update August 2026: CPHI Special Edition

As pharmaceutical innovators increasingly seek specialized manufacturing partners, small-volume commercial APIs represent a growing segment with unique development and production requirements. In this presentation, Dan Bowles, Vice President and General Manager of Cambrex's High Point, North Carolina facility, explores how CDMOs can better support emerging therapies, orphan drugs, and higher-potency compounds that may require only modest annual API volumes.

The discussion highlights Cambrex's integrated global network, spanning development, scale-up, and commercial manufacturing across North America and Europe. Bowles details recent investments at the High Point site, including expanded GMP manufacturing capacity, renovated laboratories, and a strategic focus on commercial API production in the 20-500 kg annual range. He also shares insights into building commercially viable processes, preparing for regulatory inspections, and leveraging a broader manufacturing network to support programs as they mature.

For drug developers evaluating outsourcing partners, the session offers a practical look at how scalable development expertise, operational flexibility, and targeted investments can help accelerate promising programs from clinical development to commercial success.